HAO Siguo, MD, PhD, is currently Chief Hematology Consultant at Jiahui International Hospital. He’s also the Director and Academic Leader of the Department of Hematology at Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine. He also serves as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor.

Dr. HAO earned his Ph.D. in Hematology in 2003 from Shanghai Second Medical University and the Shanghai Institute of Hematology. In 2000, he conducted advanced clinical training in hematopoietic stem cell transplantation (HSCT) as a visiting scholar at the Blood Center of Singapore General Hospital. From 2004 to 2007, he pursued postdoctoral research in tumor immunotherapy in Canada, focusing on translational applications in hematologic malignancies

Dr. HAO has almost 40 years of medical practicing experience. He specializes in the treatment of difficult and complicated hematological diseases, such as acute/chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), aplastic anemia, and anemia, thrombocytopenia caused by various reasons.

Dr. HAO has made outstanding achievements in the field of cellular immunotherapy. Since 2017, he has pioneered CAR-T cell therapy for lymphoma and multiple myeloma, accumulating extensive experience in clinical practice, particularly in managing complex and high-risk cases. He demonstrates exceptional therapeutic capabilities in challenging situations including extramedullary lesions, severe comorbidities, elderly patients, or relapsed/refractory cases after multiple lines of therapy, enabling him to develop individualized treatment plans and meticulously manage treatment-related adverse events. To date, numerous patients with complex conditions have achieved deep remission through his CAR-T treatments, with the longest disease-free survival exceeding 8 years, confirming the long-term effectiveness of his therapeutic strategies. He led a groundbreaking clinical study on CAR-T cell therapy for multiple myeloma, achieving remarkable efficacy and safety outcomes. This research was selected for oral presentations at the American Society of Hematology (ASH) Annual Meeting and the International Myeloma Working Group (IMWG) conference on multiple occasions, with the findings published in Haematologica, a top-tier hematology journal. Based on this clinical trial, "Zevor-cel" (also known as CT053) was approved by China's National Medical Products Administration (NMPA, formerly SFDA) in June 2023, becoming a widely accessible cellular therapy for patients.

Additionally, Dr. Hao has profound expertise in hematopoietic stem cell transplantation (HSCT), specializing in both autologous and allogeneic transplants (including haploidentical and umbilical cord blood transplantation). Under his leadership, Xinhua Hospital's Department of Hematology has become one of the few facilities in Shanghai performing cord blood transplants for adult malignant hematologic diseases, successfully treating nearly 100 patients with the longest disease-free survival exceeding 12 years.

Dr. HAO serves as the Vice Chairman of the 10th and 11th Shanghai Hematology Society of Chinese Medical Association, the Vice Chairman of Hematology and Oncology Branch of Shanghai Anti-Cancer Association, the member of Hematology Branch of Chinese Geriatrics Society, the member of Cord Blood Application Committee of Chinese Maternal and Child Health Association, the Vice President of Shanghai Hematopoietic Stem Cell Transplantation Alliance, the Standing Committee member of Hematology Branch of Shanghai Traditional Chinese and Western Medicine Association, the member of Expert Committee of Chinese Stem Cell Bank, the Deputy Director of Shanghai Institute of Hematology, and the member of Hematology Branch of Shanghai Immunology Society. He has undertaken and completed several provincial and ministerial scientific research projects including projects funded by National Natural Science Foundation. Dr. HAO has published more than 100 academic papers, including more than 50 SCI papers. He has presided over 4 National Natural Science Foundation projects. He has also presided several research projects of Shanghai Science and Technology Commission, Health Commission and Shanghai Shenkang Hospital Development Center. Dr. HAO also has been in charge of multiple clinical research projects. He chaired the BCMA CAR-T cell therapy for R/R multiple myeloma program, which has been communicated in several oral presentations at international congresses such as IMWG, ASH, etc., and the results of his research have also been published in the journal Haematologica 2023.